High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma

Author(s): Katharine L. Lewis, BMedSci, MBBS (Hons)^1,2,3; Lasse H. Jakobsen, PhD, MSc⁴; Diego Villa, MD, MPH⁵; Karin E. Smedby, MD⁶; Kerry J. Savage, MD, MSc⁵; Toby A. Eyre, MD, MBChB⁷; Kate Cwynarski, MD, PhD⁸; Mark J. Bishton, PhD, MBChB^9,10; Christopher P. Fox, MD, PhD^9,10; Eliza A. Hawkes, MBBS(Hons), DMedSci11,12; Matthew J. Maurer, MS, DMSc¹³; Tarec C. El-Galaly, MD, DMSc¹⁴; Chan Y. Cheah, MBBS, DMSc^1,2,3

Source: https://doi.org/10.1200/JCO.23.0036

Dr. Maen Hussein's Thoughts

Good review of high-risk patients, showing that prophylactic high dose MTX did not have lower risk of CNS disease.

PURPOSE

CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There is no consensus regarding the optimal approach to CNS prophylaxis. This study was designed to determine whether high-dose methotrexate (HD-MTX) is effective at preventing CNS progression in patients at high risk of this complication.

PATIENTS AND METHODS

Patients age 18-80 years with aggressive B-cell lymphoma and high risk of CNS progression, treated with curative-intent anti–CD20-based chemoimmunotherapy, were included in this international, retrospective, observational study. Cause-specific hazard ratios (HRs) and cumulative risks of CNS progression were calculated according to use of HD-MTX, with time to CNS progression calculated from diagnosis for all patients (all-pts) and from completion of frontline systemic lymphoma induction therapy, for patients in complete response at completion of chemoimmunotherapy (CR-pts).

RESULTS

Two thousand four hundred eighteen all-pts (HD-MTX; n = 425) and 1,616 CR-pts (HD-MTX; n = 356) were included. CNS International Prognostic Index was 4-6 in 83.4% all-pts. Patients treated with HD-MTX had a lower risk of CNS progression (adjusted HR, 0.59 [95% CI, 0.38 to 0.90]; P = .014), but significance was not retained when confined to CR-pts (adjusted HR, 0.74 [95% CI, 0.42 to 1.30]; P = .29), with 5-year adjusted risk difference of 1.6% (95% CI, –1.5 to 4.4; all-pts) and 1.4% (95% CI, –1.5 to 4.1; CR-pts). Subgroups were underpowered to draw definitive conclusions regarding the efficacy of HD-MTX in individual high-risk clinical scenarios; however, there was no clear reduction in CNS progression risk with HD-MTX in any high-risk subgroup.

CONCLUSION

In this large study, high-risk patients receiving HD-MTX had a 7.2% 2-year risk of CNS progression, consistent with the progression risk in previously reported high-risk cohorts. Use of HD-MTX was not associated with a clinically meaningful reduction in risk of CNS progression.

Author Affiliations

¹Linear Clinical Research, Nedlands, WA, Australia; ²Division of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia; ³Division of Internal Medicine, Medical School, University of Western Australia, Perth, WA, Australia; ⁴Department of Haematology, Aalborg University Hospital, Aalborg, Denmark; ⁵BC Cancer Centre for Lymphoid Cancer, The University of British Columbia, Vancouver, BC, Canada; ⁶Department of Medicine Solna, Division of Clinical Epidemiology, Karolinska Institutet, Stockholm, Sweden; ⁷Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; ⁸University College London Hospital NHS Foundation Trust, London, United Kingdom; ⁹Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; ¹⁰University of Nottingham, Nottingham, United Kingdom; ¹¹Olivia Newton-John Cancer Research & Wellness Centre at Austin Health, Heidelberg, VIC, Australia; ¹²Monash University School of Public Health and Preventive Medicine, Melbourne, VIC, Australia; ¹³Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN; ¹⁴Department of Haematology, Aalborg University Hospital, Aalborg, Denmark

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial

Median progression-free survival (PFS) was significantly longer with mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) than with R-GemOx (11.5 months vs 3.8 months). The overall response rate (ORR) was significantly higher with Mosun-Pola compared with R-GemOx (70% vs 40%; P < .0001), with complete response rates of 51% and 24%, respectively. Cytokine release syndrome (CRS) occurred in fewer than 5% of patients.

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma

Another update demonstrated the superiority of polatuzumab vedotin plus R-CHOP (Pola-R-CHOP) over R-CHOP alone, with improved progression-free survival (PFS) (64% vs 59%). Overall survival (OS) was not statistically significant; however, the hazard ratio was 0.85, with greater benefit observed in high-risk patients.

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma

Minimal residual disease (MRD) testing after two cycles of therapy and at the end of treatment predicted 2-year progression-free survival (PFS) (96% in MRD-negative patients vs 67% in MRD-positive patients). MRD status was more predictive of treatment outcomes than radiographic imaging in this patient population.

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma

The ECHELON-3 study showed BV + Len + R is an active and (relatively) tolerable in the rrDLBCL patient group. Interestingly, patients did not have to be CD30+ to see a benefit.

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study

Mosunetuzumab has an impressive response rate and durability of response in heavily pre-treated patients with B-cell NHL. This was presented at our webinar on August 7, 2024 by the cellular therapy team, slides are available upon request. We have this drug available at select sites within our practice so please contact us if you have a patient in mind.